Posted inBiotechnology
Key Factors Boosting Nursing Students’ Well-Being
In a groundbreaking study, researchers Harkin and Sarı have unveiled compelling insights into the subjective well-being of nursing students, shedding…
Posted inBiotechnology
Parents’ Views on Allergy Immunotherapy for Kids
In a groundbreaking study that has captured the attention of the scientific community, researchers from Wuxi, China, have delved deep…
Posted inMedical Technology
Optellum tapped by NHS for AI-powered lung cancer diagnostic initiative
Optellum, a 2016 spinout from the University of Oxford, has been tapped by the U.K.’s National Health Service (NHS) to…
Posted inBiotechnology
MEF2A Protects Against Stroke via PI3K/AKT Pathway
In a groundbreaking study poised to transform therapeutic strategies for ischemic stroke, researchers have unraveled the intricacies of the MEF2A-mediated…
Posted inBiotechnology
Skye links CB1-Wegovy combo to 22.3% weight loss after a year in extension of failed ph. 2 study
Skye Bioscience has published 52-week data on its investigational obesity drug combination, linking the cocktail to 22.3% total weight loss as…
Posted inBiotechnology
Roche’s return to RNA continues with $1.7B deal for Sanegene program
Roche is continuing its return to the RNA space by paying $200 million for the worldwide license to one of…
Posted inMedical Technology
A month after Alcon deal fell through, Staar Surgical searches for next CEO and names interim leaders
Staar Surgical has endured a whirlwind start to the New Year with a rejected takeover deal and the loss of…
Posted inBiotechnology
Unraveling Genome Growth in Acyclania tenebrosa
In a groundbreaking study published in BMC Genomics, researchers have delved into the genomic landscape of Acyclania tenebrosa, a noctuid…
Posted inBiotechnology
Modified FOLFIRINOX Plus Nivolumab in Pancreatic Cancer Trial
In a groundbreaking advancement in the treatment of pancreatic ductal adenocarcinoma (PDAC), a notoriously aggressive and deadly form of cancer,…
Posted inBiotechnology
Sanofi’s troubled GCS inhibitor fails phase 3 Fabry trial but scores in Gaucher disease
Sanofi’s pipeline features a number of once-hyped candidates that are struggling to deliver in the clinic, and the latest mixed…